A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.

Nze, Chijioke; Msaouel, Pavlos; Derbala, Mohamed H; Stephen, Bettzy; Abonofal, Abdulrahman; Meric-Bernstam, Funda; Tannir, Nizar M; Naing, Aung

Nze, Chijioke; Msaouel, Pavlos; Derbala, Mohamed H; Stephen, Bettzy; Abonofal, Abdulrahman; Meric-Bernstam, Funda; Tannir, Nizar M; Naing, Aung.

Afiliação

Nze C; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Msaouel P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Derbala MH; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Stephen B; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abonofal A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tannir NM; Department of Medicine, Section of Hematology/Oncology, West Virginia University, Morgantown, WV 26506, USA.
Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Cancers (Basel) ; 15(15)2023 Jul 27.

Article em En | MEDLINE | ID: mdl-37568622

Palavras-chave

SMARCB1; immunotherapy; pembrolizumab; renal medullary carcinoma

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos